<DOC>
	<DOCNO>NCT02460107</DOCNO>
	<brief_summary>The purpose study determine whether botulinum toxin A effective treatment neuropathic pain patient diabetic peripheral polyneuropathy .</brief_summary>
	<brief_title>Botulinum Toxin Type A Neuropathic Pain Patients With Diabetic Peripheral Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>• twenty year age patient 4 item positive among 10 item DN4 questionnaire . persistence neuropathic pain three month remission recurrence neuropathic pain six month pain score 4 numeric rating scale • neuropathic pain cause confounding factor diabetic neuropathic pain contraindicate botulinum toxin type A change pain medication one month prior study enrollment condition involve neuromuscular junction ( Ex . Eaton Lambert disease , myasthenia gravis ) person receive botulinum toxin type A within three month prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>